A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson's disease patients

European Journal of Neurology

Volumn 22, Issue 8, 2015, Pages 1184-1191

  Barone, P ^a   Santangelo, G ^b   Morgante, L ^c   Onofrj, M ^d   Meco, G ^e   Abbruzzese, G ^f   Bonuccelli, U ^g   Cossu, G ^h   Pezzoli, G ⁱ   Stanzione, P ^j   Lopiano, L ^k   Antonini, A ^l   Tinazzi, M ^m  

^a UNIVERSITY OF SALERNO   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF CHIETI   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF PISA   (Italy)

^h BROTZU HOSPITAL   (Italy)

ⁱ PARKINSON INSTITUTE   (Italy)

^j IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^k UNIVERSITY OF TURIN   (Italy)

^l IRCCS SAN CAMILLO HOSPITAL   (Italy)

^m UNIVERSITY OF VERONA   (Italy)

more..

Author keywords

Cognition; Depression; Parkinson's disease; Rasagiline

Indexed keywords

PLACEBO; RASAGILINE; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT;

AGED; ARTICLE; BECK DEPRESSION INVENTORY; COGNITION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARKINSON DISEASE; PIGMENTED NEVUS; POLYNEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SYMPTOMATOLOGY; UNIFIED PARKINSON DISEASE RATING SCALE; VERTIGO; COMPLICATION; MIDDLE AGED; TREATMENT OUTCOME;

AGED; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TREATMENT OUTCOME;

EID: 84935702240     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12724     Document Type: Article

References (19)

1. Dooneief G, Mirabello E, Bell K, et al. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992; 49: 305-307.
2. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996; 53: 175-179.
3. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007; 69: 342-347.
4. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229-1236.
5. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord 2005; 20: 1161-1169.
6. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886-892.
7. Ehmann TS, Beninger RJ, Gawel MJ, Riopelle RJ. Depressive symptoms in Parkinson's disease: a comparison with disabled control subjects. J Geriatr Psychiatry Neurol 1990; 3: 3-9.
8. Weintraub D, Burn DJ. Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord 2011; 26: 1022-1031.
9. Leentjens AF. Depression in Parkinson's disease: conceptual issues and clinical challenges. J Geriatr Psychiatry Neurol 2004; 17: 120-126.
10. Storch A, Schneider CB, Wolz M, et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurology 2013; 80: 800-809.
11. Yarnall AJ, Rochester L, Burn DJ. Mild cognitive impairment in Parkinson's disease. Age Ageing 2013; 42: 567-576.
12. McCormack PL. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease. CNS Drugs 2014; 28: 1083-1097.
13. Poewe W, Hauser R, Lang A. Effects of rasagiline on the progression of non-motor scores of the MDS-UPDRS. Mov Disord 2015; 30: 589-592.
14. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011; 10: 415-423.
15. Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011; 26: 1851-1858.
16. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573-580.
17. Ishibashi K, Ishii K, Oda K, Mizusawa H, Ishiwata K. Binding of pramipexole to extrastriatal dopamine D2/D3 receptors in the human brain: a positron emission tomography study using 11C-FLB 457. PLoS One 2011; 6: e17723.
18. Rajagopal S. The placebo effect. Psychiatr Bull 2006; 30: 185-188.
19. Smith KM, Eyal EWeintraub D, ADAGIO Investigators. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability. JAMA Neurol 2015; 72: 88-95.